Pulse Biosciences Schedules First Quarter 2022 Financial Results Conference Call for May 11, 2022
April 28 2022 - 8:00AM
Business Wire
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric
medicine company commercializing the CellFX® System powered by
Nano-Pulse Stimulation™ (NPS™) technology, announced today it will
report financial results for the first quarter of 2022 after market
close on Wednesday, May 11, 2022. Company management will host a
corresponding conference call beginning at 1:30pm PT.
Investors interested in listening to the conference call may do
so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920
for international callers. A live and recorded webcast of the event
will be available at http://investors.pulsebiosciences.com/.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company
committed to health innovation that has the potential to improve
the quality of life for patients. The CellFX® System is the first
commercial product to harness the distinctive advantages of the
Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology,
such as the ability to nonthermally clear cells while sparing
non-cellular tissue, to treat a variety of applications for which
an optimal solution remains unfulfilled. Nano-Pulse Stimulation
technology delivers nano-second pulses of electrical energy. The
initial commercial use of the CellFX System is to address a range
of dermatologic conditions that share high demand among patients
and practitioners for improved dermatologic outcomes. Designed as a
multi-application platform, the CellFX System offers customer value
with a utilization-based revenue model. To learn more, please visit
pulsebiosciences.com.
To stay informed about the CellFX System, please visit
CellFX.com and sign up for updates.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the
stylized logos are among the trademarks and/or registered
trademarks of Pulse Biosciences, Inc. in the United States and
other countries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220428005335/en/
Investors: Pulse Biosciences Sandra Gardiner, EVP and CFO
510.241.1077 IR@pulsebiosciences.com or Gilmartin Group Philip Trip
Taylor 415.937.5406 philip@gilmartinir.com
Media: Tosk Communications Nadine D. Tosk 504.453.8344
press@pulsebiosciences.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Apr 2023 to Apr 2024